CALU and lung cancer: To investigate the protein alteration of the candidate signature biomarkers through cancer progression, the protein level of CALU, AURKA, and MCM2 was analyzed between 40 biopsy specimens and matched adjacent healthy tissues collected from CRC and lung cancer patients.